Eli Lilly & Co. (LLY: Quote) announced results from its Phase 3 EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease Monday afternoon. The results showed that patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo.
Eli Lilly & Co. climbed steadily following the release of the study results and finished up by 2.55 at $50.78 on strong volume. The stock has been rising for the past week and surged to a new high for the year.
Click here to receive FREE breaking news email alerts for Eli Lilly And Co. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org